Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. It develops BIV201, which completed Phase 2a clinical trial for the treatment of ascites due to chronic liver cirrhosis. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was founded in 2013 and is based in Santa Monica, California.
Website: biovieinc.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 4.3% (LTM)

Entry Point: Share price is 2 445.1% higher than minimum and 44.1% lower than maximum for the last 3 years

Key Financials (Download financials)

Ticker: BIVI
Share price, USD:  (-0.9%)7.48
year average price 2.11  


year start price 0.47 2024-07-27

min close price 0.29 2024-08-05

max close price 9.00 2025-07-18

current price 7.48 2025-07-26
Common stocks: 18 507 218

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue):
Fundamental value created in LTM:
Market Cap ($m): 138
Net Debt ($m): -5
EV (Enterprise Value): 133
Price to Book: 9.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-14globenewswire.com

BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025

2025-04-30globenewswire.com

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

2025-01-02globenewswire.com

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

2024-12-11accesswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against BioVie Inc. (BIVI) and Encourages Stockholders to Learn More About the Investigation

2024-10-28globenewswire.com

UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2024-10-28globenewswire.com

BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

2024-10-22globenewswire.com

BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement

2024-10-21globenewswire.com

BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

2024-09-25globenewswire.com

BioVie Inc. Announces Closing of Public Offering

2024-09-23globenewswire.com

BioVie Inc. Announces Pricing of Public Offering
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BIVI BIVI BIVI BIVI BIVI BIVI BIVI BIVI BIVI
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-13 2024-09-30 2024-05-14 2024-02-13 2023-11-08 2023-08-16 2023-05-12 2023-02-10 2022-11-04
acceptedDate 2024-11-13 16:46:12 2024-09-30 17:08:37 2024-05-14 17:06:16 2024-02-12 18:30:09 2023-11-08 16:30:31 2023-08-16 17:30:16 2023-05-12 17:16:08 2023-02-10 17:16:25 2022-11-04 17:15:45
calendarYear 2025 2024 2024 2024 2024 2023 2023 2023 2023
period Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
revenue 0 0 0 0 0 0 0 0 0
costOfRevenue 57 344 57 344 57 344 57 344 67 385 0 0 0 0
grossProfit -57 344 -57 344 -57 344 -57 344 -67 385 0 0 0 0
grossProfitRatio 0 0 0 0 0 0 0 0 0
researchAndDevelopmentExpenses 2M 2M 6M 6M 9M 8M 11M 7M 7M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 2M 3M 2M 2M 2M 3M 3M 4M 2M
otherExpenses 0 57 344 57 344 57 344 57 344 229M 57 344 57 344 57 344
operatingExpenses 4M 5M 8M 9M 11M 11M 14M 11M 9M
costAndExpenses 4M 5M 8M 9M 11M 11M 14M 11M 9M
interestIncome 223 557 272 517 183 933 218 029 462 223 255 209 182 201 83 269 41 585
interestExpense 256 024 439 943 628 711 820 600 1M 1M 1M 1M 1M
depreciationAndAmortization 57 344 57 344 57 344 57 344 57 344 57 344 239 545 149 846 107 912
ebitda -4M -4M -8M -9M -10M -11M -14M -11M -9M
ebitdaratio 0 0 0 0 0 0 0 0 0
operatingIncome -4M -5M -8M -9M -11M -11M -14M -11M -9M
operatingIncomeRatio 0 0 0 0 0 0 0 0 0
totalOtherIncomeExpensesNet -29 950 -150 494 -330 560 982 534 707 802 3M -1M -4M -2M
incomeBeforeTax -4M -5M -8M -8M -11M -9M -15M -16M -10M
incomeBeforeTaxRatio 0 0 0 0 0 0 0 0 0
incomeTaxExpense 0 0 -4 820 600 1M 1M 183 892 3M 566 542
netIncome -4M -5M -8M -8M -11M -9M -15M -19M -11M
netIncomeRatio 0 0 0 0 0 0 0 0 0
eps -0.7 -0.8 -0.18 -0.22 -0.29 -0.25 -0.43 -0.61 -0.4
epsdiluted -0.7 -0.8 -0.18 -0.22 -0.29 -0.25 -0.43 -0.61 -0.4
weightedAverageShsOut 6M 6M 45M 38M 37M 36M 35M 31M 27M
weightedAverageShsOutDil 6M 6M 45M 38M 37M 36M 35M 31M 27M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BIVI BIVI BIVI BIVI BIVI BIVI BIVI BIVI BIVI
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-13 2024-09-30 2024-05-14 2024-02-13 2023-11-08 2023-08-16 2023-05-12 2023-02-10 2022-11-04
acceptedDate 2024-11-13 16:46:12 2024-09-30 17:08:37 2024-05-14 17:06:16 2024-02-12 18:30:09 2023-11-08 16:30:31 2023-08-16 17:30:16 2023-05-12 17:16:08 2023-02-10 17:16:25 2022-11-04 17:15:45
calendarYear 2025 2024 2024 2024 2024 2023 2023 2023 2023
period Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
cashAndCashEquivalents 20M 24M 30M 20M 21M 19M 31M 46M 21M
shortTermInvestments 0 0 0 0 0 14M 13M 0 0
cashAndShortTermInvestments 20M 24M 30M 20M 21M 34M 44M 46M 21M
netReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
otherCurrentAssets 127 680 204 392 189 582 334 963 2M 102 526 249 790 241 282 359 123
totalCurrentAssets 20M 24M 31M 21M 23M 34M 44M 46M 22M
propertyPlantEquipmentNet 390 777 406 726 422 169 60 418 70 748 80 789 90 549 100 038 109 271
goodwill 345 711 345 711 345 711 345 711 345 711 345 711 345 711 345 711 345 711
intangibleAssets 350 374 407 718 465 062 522 407 579 751 637 095 694 439 751 784 809 128
goodwillAndIntangibleAssets 696 085 753 429 810 773 868 118 925 462 982 806 1M 1M 1M
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 0 0 -1 0 -0 0 4562 4562 4562
totalNonCurrentAssets 1M 1M 1M 928 536 996 210 1M 1M 1M 1M
otherAssets 0 0 1 0 -0 0 0 0 0
totalAssets 21M 25M 32M 21M 24M 35M 45M 47M 23M
accountPayables 0 4M 4M 3608.096 2714.76 0 0 3M 0
shortTermDebt 3M 6M 8M 10M 9M 9M 6M 41 788 40 317
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 -4M -3608.096 -2714.76 0 0 0 0
otherCurrentLiabilities 3M 3771 4M 4M 4M 5M 10M 5M 4M
totalCurrentLiabilities 7M 9M 12M 14M 13M 14M 16M 8M 4M
longTermDebt 332 730 349 894 366 430 17 604 3M 5M 7M 13M 13M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 0 -1 0 -0 0 0 0 13M
totalNonCurrentLiabilities 332 730 349 894 366 429 17 604 3M 5M 7M 13M 13M
otherLiabilities 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 396 394 410 237 366 430 65 835 76 769 87 414 97 779 107 623 117 085
totalLiabilities 7M 10M 13M 14M 16M 20M 23M 21M 17M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 6406 6229 6115 3984 3690 3643 3613 3449 3015
retainedEarnings -339M -334M -329M -320M -312M -301M -292M -277M -261M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 176 591 16 505 0 0
othertotalStockholdersEquity 353M 350M 348M 328M 319M 316M 314M 303M 267M
totalStockholdersEquity 14M 16M 19M 7M 8M 15M 22M 26M 6M
totalEquity 14M 16M 19M 7M 8M 15M 22M 26M 6M
totalLiabilitiesAndStockholdersEquity 21M 25M 32M 21M 24M 35M 45M 47M 23M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 21M 25M 32M 21M 24M 35M 45M 47M 23M
totalInvestments 0 0 0 0 0 14M 13M 0 0
totalDebt 4M 6M 8M 10M 12M 14M 14M 13M 13M
netDebt -16M -18M -22M -10M -9M -5M -17M -32M -8M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol BIVI BIVI BIVI BIVI BIVI BIVI BIVI BIVI BIVI
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-13 2024-09-30 2024-05-14 2024-02-13 2023-11-08 2023-08-16 2023-05-12 2023-02-10 2022-11-04
acceptedDate 2024-11-13 16:46:12 2024-09-30 17:08:37 2024-05-14 17:06:16 2024-02-12 18:30:09 2023-11-08 16:30:31 2023-08-16 17:30:16 2023-05-12 17:16:08 2023-02-10 17:16:25 2022-11-04 17:15:45
calendarYear 2025 2024 2024 2024 2024 2023 2023 2023 2023
period Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
netIncome -4M -5M -8M -8M -11M -9M -15M -16M -10M
depreciationAndAmortization 57 344 57 344 57 344 57 344 57 344 57 344 39 129 66 577 66 327
deferredIncomeTax 0 0 0 -982 534 761 499 -3M 0 0 0
stockBasedCompensation 301 491 2M 1M 922 874 1M 1M 906 534 3M 896 177
changeInWorkingCapital 0 -850 988 934 709 2M -2M -1M 1M 586 303 -920 383
accountsReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables 0 0 0 0 -761 499 1 032M 0 802 610 179 530
otherWorkingCapital -71 071 -850 988 934 709 2M 761 499 -1 034M 0 -216 307 -1M
otherNonCashItems 213 741 206 817 1M 397 185 -1M 545 404 929 440 4M 1M
netCashProvidedByOperatingActivities -4M -4M -6M -6M -12M -11M -12M -8M -9M
investmentsInPropertyPlantAndEquipment 0 -1 0 0 0 0 0 0 0
acquisitionsNet 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 -2M 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 15M 0 0 0 0
otherInvestingActivites 0 0 0 0 14 525 0 0 0 0
netCashUsedForInvestingActivites 0 0 0 0 15M -2M 0 0 0
debtRepayment -3M -3M -3M -3M -3M 0 0 0 0
commonStockIssued 2M 0 18M 7M 2M 1M 10M 33M 12M
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 18M 7421.878 -594.164 0 0 2240 0
netCashUsedProvidedByFinancingActivities -240 937 -3M 16M 5M -594 164 1M 10M 33M 12M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0
netChangeInCash -4M -7M 10M -987 972 2M -12M -14M 25M 3M
cashAtEndOfPeriod 20M 24M 30M 20M 21M 19M 31M 46M 21M
cashAtBeginningOfPeriod 24M 30M 20M 21M 19M 31M 46M 21M 19M
operatingCashFlow -4M -4M -6M -6M -12M -11M -12M -8M -9M
capitalExpenditure 0 -1 0 0 0 0 0 0 0
freeCashFlow -4M -4M -6M -6M -12M -11M -12M -8M -9M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

Press-releases

Show financial reports only

2024-08-27 12:45 ET
BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting
2024-08-13 12:00 ET
BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting
2024-08-06 20:40 ET
BioVie Inc. Announces Reverse Stock Split
2024-07-05 13:00 ET
BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2024-06-25 12:00 ET
BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at ATMRD 2024
2024-06-21 13:00 ET
BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2024-06-20 12:00 ET
BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson’s Disease at 2024 ATMRD Congress
2024-06-12 12:24 ET
Join BioVie’s Exclusive Live Investor Webinar and Q&A Session on June 26
2024-06-04 12:00 ET
BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID
2024-05-22 12:00 ET
BioVie’s Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients
2024-04-29 12:00 ET
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
2024-04-29 12:00 ET
BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID
2024-04-25 12:00 ET
BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer’s Disease and Biomarker Endpoints
2024-04-18 12:00 ET
BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation
2024-04-12 13:00 ET
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2024-03-11 12:00 ET
BioVie Announces Pipeline Update and Near-Term Clinical Priorities
2024-03-07 02:06 ET
ATTENTION BIOVIE INC. Shareholders: Securities Fraud Lawsuit Filed Against BioVie Inc. (BIVI)
2024-03-07 02:06 ET
ATTENTION BIOVIE INC. Shareholders: Securities Fraud Lawsuit Filed Against BioVie Inc. (BIVI)
2024-03-06 22:00 ET
BioVie Inc. Announces Closing of Public Offering
2024-03-04 06:32 ET
BioVie Inc. Announces Pricing of Public Offering
2024-03-01 21:58 ET
BioVie Inc. Announces Proposed Public Offering of Common Stoc
2024-03-01 13:00 ET
BioVie’s NE3107 Demonstrates Potential Improvements in Motor and Non-motor Symptoms for Parkinson’s Disease Patients and May Be Realigning Physiological Processes for Alzheimer’s Patients in Data to be Presented at the International Conference on Alzh...
2024-02-09 14:36 ET
STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against BioVie Inc. (BIVI)
2024-02-09 14:36 ET
STOCKHOLDER ALERT: Pending Securities Fraud Lawsuit Against BioVie Inc. (BIVI)
2024-02-06 13:00 ET
BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
2024-01-05 14:00 ET
bioAffinity Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
2023-12-29 14:00 ET
Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
2023-12-22 14:00 ET
Rail Vision and BioVie Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV
2023-11-29 13:00 ET
BioVie Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease
2023-11-13 13:00 ET
BioVie Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023
2023-11-02 12:00 ET
BioVie to Participate in the Truist Securities BioPharma Symposium
2023-10-30 17:00 ET
BioVie CEO reveals stunning results in Alzheimer's and Parkinson's drug trial
2023-10-30 12:00 ET
BioVie to Host Conference Call and Webcast Wednesday November 1, 2023 at 8:00 AM ET
2023-10-26 12:00 ET
BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company’s Ascites Phase 2 Trial Accepted for Presentation at AASLD – The Liver Meeting® 2023
2023-10-25 16:30 ET
Blinded Data Presented at CTAD Suggest that NE3107 is Biologically Active and May Have Impact on Cognitive, Biomarker, and Imaging Endpoints Among Mild to Moderate Alzheimer’s Disease Patients
2023-10-19 11:30 ET
BioVie to Present Blinded Data on NE3107 in the Treatment of Mild to Moderate Alzheimer’s Disease at CTAD
2023-09-26 12:00 ET
BioVie Announces Completion of Last Patient Treatment Visit in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer's Disease
2023-09-20 12:45 ET
BioVie's Lead Drug Candidate Aims To Treat Neurodegenerative Disease By Targeting Inflammation
2023-09-19 12:00 ET
BioVie to Participate in the Cantor Fitzgerald Global Healthcare Conference
2023-09-12 18:10 ET
BioVie chief social impact officer sees major need for Alzheimer’s support and research
2023-09-11 12:00 ET
BioVie Presents Data Highlighting Baseline Characteristics of Study Population in Phase 3 Trial of NE3107 in Mild to Moderate Alzheimer’s Disease
2023-09-07 12:00 ET
BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer’s Disease Today, September 7, 2023
2023-08-31 12:00 ET
BioVie to Host Virtual KOL Event on NE3107 in Alzheimer’s Disease on September 7, 2023
2023-08-28 12:00 ET
BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson’s Disease and Movement Disorders
2023-08-11 14:05 ET
BioVie and Soligenix Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
2023-07-20 17:06 ET
BioVie issues letter to shareholders; highlights latest update on NE3107 for Alzheimer's Disease
2023-07-18 11:00 ET
BioVie Issues Letter to Shareholders
2023-07-17 11:00 ET
BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease
2023-07-13 20:26 ET
BioVie to present neurodegenerative research at Alzheimer’s Associate’s International Conference
2023-07-10 12:00 ET
BioVie to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease
2023-06-28 16:59 ET
BioVie building healthier future for families and caregivers dealing with neurodegenerative diseases
2023-06-26 12:00 ET
BioVie Presents Data Highlighting Role of Insulin Resistance and Neuroinflammation in the Development of Mild to Moderate in Alzheimer’s Disease
2023-06-23 12:00 ET
BioVie Set to Join the Russell 2000® and Russell 3000® Indexes
2023-06-21 12:00 ET
BioVie To Present of NE3017 in Alzheimer’s Disease Data at 83rd Scientific Sessions of the American Diabetes Association
2023-06-15 17:15 ET
BioVie research and social impact initiatives recognize Alzheimer's & Brain Awareness Month
2023-05-16 20:05 ET
BioVie Presents Rationale for Potentially Pivotal Trial of NE3107 in the Treatment of Parkinson’s Disease at 2023 International Association of Parkinsonism and Related Disorders World Congress
2023-04-20 12:30 ET
BioVie To Present Data from NE3107 Phase 2 Open-Label Trial at Society of Biological Psychiatry Annual Meeting
2023-04-17 12:00 ET
BioVie Announces Data Abstracts from NE3107 Phase 2 Trials Accepted for Presentation at AAN 2023
2023-03-24 12:30 ET
BioVie Inc. and iRemedy Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)
2023-03-21 12:01 ET
BioVie Announces Data from Phase 2 Parkinson’s Disease Trial Accepted for Presentation at AD/PD 2023
2023-03-15 14:59 ET
BioVie Day says webinar registration now open for investors
2023-03-14 12:00 ET
BioVie Announces Registration Details for "BioVie Day" Webinar
2023-03-13 12:00 ET
BioVie Announces the Pausing of Patient Enrollment in Ascites Phase 2b Trial, Encouraging Efficacy Data is Announced, Initiating FDA Discussions to Conduct Pivotal Registrational Trial
2023-03-09 13:00 ET
BioVie to Participate in the Oppenheimer 33rd Annual Healthcare Conference
2023-03-06 13:00 ET
BioVie Announces Additional Findings from Phase 2 Parkinson’s Disease Trial: More patients treated with NE3107 experienced morning “on state” with levodopa withheld overnight compared to those treated with placebo
2023-03-02 13:00 ET
BioVie Announces Completion of Patient Enrollment in Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease
2023-02-21 13:00 ET
BioVie Announces “BioVie Day” to be held March 23, 2023
2022-12-29 13:30 ET
BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
2022-12-13 13:05 ET
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Cuong Do, President & CEO BioVie Inc.
2022-12-07 13:00 ET
BioVie Issues Letter to Shareholders
2022-12-06 11:00 ET
BioVie Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: NE3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia
2022-12-05 22:00 ET
BioVie Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials
2022-11-29 13:00 ET
BioVie’s Phase 3 Trial Assessing NE3107 in Alzheimer’s Disease Has Fully Enrolled the Targeted 316 Patients
2022-11-15 13:00 ET
BioVie to Present Data from Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer's Disease at CTAD Annual Meeting
2022-10-24 12:00 ET
BioVie to Present Data on Characterizing Hospitalization Burden of Ascites at AASLD Liver Meeting 2022
2022-10-19 10:00 ET
BioVie’s Phase 2 Trial Assessing NE3107's Pro-motoric Activity in Parkinson's Disease is Fully Enrolled
2022-10-04 12:00 ET
BioVie Issues Letter to Shareholders
2022-09-29 12:00 ET
BioVie to Participate in Cantor Fitzgerald’s Neurology & Psychiatry Conference
2022-09-15 12:10 ET
BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
2022-09-07 10:00 ET
BioVie and Dr. Sheldon Jordan Jointly Announce Topline Results from an Investigator-Sponsored Exploratory Biomarker and Imaging Trial of NE3107 for the Treatment of Alzheimer’s Disease
2022-06-23 12:00 ET
BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201
2022-04-25 12:00 ET
BioVie to Participate at the B. Riley Securities’ Neuro & Ophthalmology Conference
2022-03-10 13:00 ET
BioVie Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®
2022-03-09 21:05 ET
BioVie to Participate at the Oppenheimer Virtual Annual Healthcare Conference
2022-01-20 13:00 ET
BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease
2021-12-28 13:00 ET
BioVie to Participate at the LifeSci Partners 11th Annual Corporate Access Event
2021-12-09 13:00 ET
BioVie Announces Partnership with the American Liver Foundation
2021-12-01 13:00 ET
BioVie Secures Up to a $25.0 Million Debt Facility with Avenue Venture Opportunities Fund, L.P. and Avenue Venture Opportunities Fund II, L.P.
2021-11-04 12:00 ET
BioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis and BIV201 Phase 2b Clinical Trial Update 
2021-11-01 12:00 ET
BioVie Announces the Appointment of a New Chief Medical Officer
2021-10-26 12:00 ET
BioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107’s Pro-motoric Activity in Parkinson’s Disease
2021-10-13 12:00 ET
BioVie Hosting Key Opinion Leader Webinar on Neuroinflammation and Insulin Resistance and New Treatment Approaches for Alzheimer’s Disease
2021-09-22 12:00 ET
BioVie to Present at Cantor Virtual Global Healthcare Conference
2021-09-15 20:01 ET
BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit
2021-08-11 17:14 ET
BioVie Inc. Announces Closing of Public Offering of Common Stock
2021-08-09 01:28 ET
BioVie Inc. Announces Pricing of Public Offering of Common Stock
2021-08-06 21:30 ET
BioVie Inc. Announces Proposed Public Offering of Common Stock
2021-08-05 12:00 ET
BioVie Announces First Patient Enrolled in Phase 3 Study of NE3107 in Alzheimer’s Disease
2021-07-27 12:00 ET
BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
2021-07-22 12:00 ET
BioVie to Present Rationale for use of NE3107 for the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference
2021-07-16 12:00 ET
Basis for BioVie’s Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer’s Disease Published in Neurodegenerative Disease Management
2021-06-29 12:00 ET
Development of BioVie’s NE3107 Asset Featured by the American Diabetes Association
2021-06-28 12:00 ET
BioVie Added to Russell Microcap® Index
2021-06-25 12:00 ET
BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
2021-06-24 12:00 ET
BioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites
2021-06-23 12:00 ET
BioVie Receives FDA Guidance for Phase 3 Clinical Trial of BIV201 in HRS-AKI
2021-06-17 20:05 ET
BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
2021-06-11 12:00 ET
BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix
2021-05-12 12:00 ET
BioVie Hosting Research & Development Day
2021-05-10 12:19 ET
BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix
2021-04-28 11:00 ET
BioVie to Present at 2021 B. Riley Securities’ Neuroscience Conference
2021-04-27 20:05 ET
BioVie Acquires Biopharma Assets from Privately Held NeurMedix
2021-03-11 12:00 ET
BioVie to Present at 31st Annual Oppenheimer Healthcare Conference
2021-03-09 12:00 ET
BioVie Commences Patient Screening in Phase 2 Clinical Trial
2021-02-19 12:00 ET
BioVie Interview to Air on Bloomberg TV in the US on the RedChip Money Report®
2020-10-30 12:00 ET
BioVie Interview to Air on Bloomberg International on the RedChip Money Report
2020-10-29 12:00 ET
BioVie to Participate in B. Riley Securities Liver Disease Therapeutics Day on October 29, 2020
2020-09-23 12:00 ET
BioVie Announces Closing of Public Offering of Common Stock
2020-09-21 11:00 ET
BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & Medtech Summit
2020-09-17 23:55 ET
BioVie Inc. Announces Nasdaq Listing and Pricing of $15.7 Million Public Offering
2020-06-16 12:30 ET
Highly Accomplished Executives Join BioVie’s Board of Directors
2020-06-11 12:30 ET
BioVie Advances the BIV201 Clinical Program and Prefilled Syringe
2019-10-22 11:00 ET
BioVie Submits Protocol for Phase 2b/3 Refractory Ascites Study to FDA

SEC forms

Show financial reports only

SEC form 10
2025-05-12 21:15 ET
BioVie reported for 2025 q1
SEC form 10
2025-05-12 00:00 ET
BioVie reported for 2025 q1
SEC form 10
2025-02-11 22:00 ET
BioVie reported for 2024 q4
SEC form 10
2025-02-11 00:00 ET
BioVie reported for 2024 q4
SEC form 10
2024-11-13 16:46 ET
BioVie reported for 2024 q3
SEC form 10
2024-11-13 00:00 ET
BioVie reported for 2024 q3
SEC form 10
2024-09-30 00:00 ET
BioVie reported for 2024 q2
SEC form 10
2024-05-14 17:06 ET
BioVie reported for 2024 q1
SEC form 10
2024-05-14 00:00 ET
BioVie reported for 2024 q1
SEC form 10
2024-02-13 00:00 ET
BioVie reported for 2023 q4
SEC form 10
2024-02-12 18:30 ET
BioVie reported for 2023 q4
SEC form 10
2023-11-08 16:30 ET
BioVie reported for 2023 q3
SEC form 10
2023-11-08 00:00 ET
BioVie reported for 2023 q3
SEC form 10
2023-08-16 17:30 ET
BioVie reported for 2023 q2
SEC form 10
2023-08-16 00:00 ET
BioVie reported for 2023 q2
SEC form 10
2023-05-12 17:16 ET
BioVie reported for 2023 q1
SEC form 10
2023-05-12 00:00 ET
BioVie reported for 2023 q1
SEC form 6
2023-04-06 17:44 ET
BioVie published news for 2023 q1
SEC form 6
2023-03-23 17:06 ET
BioVie published news for 2022 q4
SEC form 10
2023-02-10 00:00 ET
BioVie reported for 2022 q4
SEC form 10
2022-11-04 00:00 ET
BioVie reported for 2022 q3
SEC form 10
2022-09-27 00:00 ET
BioVie reported for 2022 q2
SEC form 10
2022-05-11 00:00 ET
BioVie reported for 2022 q1
SEC form 10
2022-02-08 00:00 ET
BioVie published news for 2021 q4
SEC form 10
2021-11-10 00:00 ET
BioVie published news for 2021 q3
SEC form 10
2021-08-30 00:00 ET
BioVie published news for 2021 q2
SEC form 10
2021-05-10 00:00 ET
BioVie published news for 2021 q1